Inhibikase Therapeutics, Inc.
General ticker "IKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $181.8M (TTM average)
Inhibikase Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -12.1%.
Estimated limits based on current volatility of 3.2%: low 1.68$, high 1.79$
Factors to consider:
- Total employees count: 14 as of 2023
- Top business risk factors: Going concern, Capital raising, Economic downturns and volatility, Pandemic risks, Litigation risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.20$, 2.86$]
- 2026-12-31 to 2027-12-31 estimated range: [1.19$, 2.81$]
Short-term IKT quotes
Long-term IKT plot with estimates
Financial data
| YTD | 2025-12-31 |
|---|---|
| Operating Revenue | $0.00MM |
| Operating Expenses | $45.95MM |
| Operating Income | $-45.95MM |
| Non-Operating Income | $-2.31MM |
| R&D Expense | $29.79MM |
| Income(Loss) | $-48.26MM |
| Profit(Loss)* | $-48.26MM |
| Stockholders Equity | $172.90MM |
| Assets | $181.20MM |
| Operating Cash Flow | $-27.79MM |
| Capital expenditure | $0.01MM |
| Investing Cash Flow | $2.05MM |
| Financing Cash Flow | $108.46MM |
| Earnings Per Share** | $-0.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.